GM(GM) GlobeNewswire News Room·2025-05-07 21:10Core Points - Knight Therapeutics Inc. held its Annual General Meeting of Shareholders virtually in Montreal, Quebec, where key voting results were announced [1] Group 1: Election of Directors - All director nominees listed in the Management Information Circular dated April 4, 2025, were elected as Directors of the Corporation [2] - Jonathan Ross Goodman received 59,911,976 votes (96.70% for) and 2,041,772 votes (3.30% against) [2] - James C. Gale received 61,421,942 votes (99.14% for) and 531,806 votes (0.86% against) [2] - Samira Sakhia received 61,868,351 votes (99.86% for) and 85,397 votes (0.14% against) [2] - Robert N. Lande received 61,742,628 votes (99.66% for) and 211,120 votes (0.34% against) [2] - Michael J. Tremblay received 59,558,152 votes (96.13% for) and 2,395,596 votes (3.87% against) [2] - Nicolás Sujoy received 61,749,390 votes (99.67% for) and 204,358 votes (0.33% against) [2] - Janice Murray received 61,750,229 votes (99.67% for) and 203,519 votes (0.33% against) [2] Group 2: Appointment of External Auditors - Ernst & Young LLP was appointed as external auditors for the next year with 62,087,609 votes (99.60% for) and 248,512 votes (0.40% withheld) [3] Group 3: Employee and Director Share Purchase Plan - The resolution to renew unallocated rights under the Corporation's employee and director share purchase plan was approved with 54,409,705 votes (87.82% for) and 7,544,043 votes (12.18% against) [4] Group 4: Company Overview - Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, focusing on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America [5] - The company's Latin American subsidiaries operate under United Medical, Biotoscana Farma, and Laboratorio LKM [5] - Knight Therapeutics Inc.'s shares are traded on TSX under the symbol GUD [5]